Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

The U.S. Federal Trade Commission on Tuesday published the second part of its investigation into how prescription drug ...

The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

CVS responds by saying regulator's latest report is 'inappropriate and misleading' The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday ...

A proposed Arkansas law would forbid pharmacy benefit managers (PBMs) from holding or acquiring interest in retail pharmacy ...

See: FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%. Also read: UnitedHealthcare head Brian Thompson's killing shines light on health-insurance denial rates.

On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...

(CNN) — Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty ...